Recent progress in toxicogenomics research in South Korea.
BACKGROUND
The importance of toxicogenomics was recognized early in Korea and a group of researchers was trying to build up a research infrastructure and educational system. However, since the scale of the Korean pharmaceutical industry, which was expected to play the key role in toxicogenomics was small compared to that of advanced countries, industry-sponsored large-scale research projects and supporting infrastructures have been lacking in Korea.


RESULTS
To improve this situation, the Korean government has exerted special efforts to promote toxicogenomics research and development the last few years as an initiative to stimulate a premature drug development industry on par with global competition and launched several large scale research projects recently. Researchers are also trying to keep pace with government efforts by organizing local scientist groups, training young toxicogenomics scientists, and widening the toxicogenomic research efforts to environmental toxicity as well. Research and development from bioinformatics and genomics venture companies are also contributing to uplifting the competitiveness of the toxicogenomics industry.


CONCLUSIONS
Toxicogenomics in Korea is making steady progress in many directions. It is gaining ground by government and related industries as well, the research is diversified to embrace environmental genomics, and local research groups are making strategic links to international research groups such as the MicroArray Quality Control (MAQC) consortium. We expect the advancement of the Korean toxicogenomics research program will be beneficial not only to the local society alone, but also to international scientists as a whole.
Chung
Tae-Hoon
TH
Korea Biobank, Center for Genome Science, Korea National Institute of Health, Korea Centers for Disease Control and Prevention, 194 Tongil-lo, Eunpyung-gu, Seoul, 122-701, Republic of Korea. hoontaechung@gmail.com
Yoo
Jin-Ho
JH
Ryu
Jae-Chun
JC
Kim
Yang-Seok
YS